top of page
MRK: As predicted, Winrevair in PH group 2 CADENCE is positive. What's the opportunity?
As expected, Winrevair CADENCE is positive in wider Pul HT
As predicted in our Feb 2024 Foveal research soteracept report “One big hit”, the phase II CADENCE trial improved haemodynamics in a subgroup of common heart failure, being the first evidence of utility outside Group 1 pulmonary hypertension (PAH), for which Winrevair is already approved.
bottom of page